MedPath

神州细胞工程有限公司

Ownership
-
Established
2002-06-27
Employees
-
Market Cap
-
Website
http://cn.sinobiological.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

8

NMPA:8

Drug Approvals

Finotonlimab Injection

Product Name
安佑平
Approval Number
国药准字S20250011
Approval Date
Feb 8, 2025
NMPA

Bevacizumab Injection

Product Name
安贝珠
Approval Number
国药准字S20230035
Approval Date
Jun 27, 2023
NMPA

Adalimumab Injection

Product Name
安佳润
Approval Number
国药准字S20230034
Approval Date
Jun 7, 2023
NMPA

Ripertamab Injection

Product Name
安平希
Approval Number
国药准字S20220026
Approval Date
Aug 23, 2022
NMPA

Ripertamab Injection

Product Name
安平希
Approval Number
国药准字S20220025
Approval Date
Aug 23, 2022
NMPA

Ripertamab Injection

Product Name
安平希
Approval Number
国药准字S20220024
Approval Date
Aug 23, 2022
NMPA

Omfiloctocog alfa for Injection

Product Name
安佳因
Approval Number
国药准字S20210031
Approval Date
Jul 20, 2021
NMPA

Omfiloctocog alfa for Injection

Product Name
安佳因
Approval Number
国药准字S20210032
Approval Date
Jul 20, 2021
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.